A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Jack Gilleland
| Share Statistics | ERNA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $7.0 | $282.4 | 5% |
|
| Shares Out (Mil) | 1.2 | 54.0 | 5% |
|
| Institutional Ownership | 23.4% | 93.1% | 11% |
|
| Float (Mil) | 1.2 | 42.2 | 3% |
|
| Beta | 2.56 | 0.94 | 96% |
|
| Avg Daily Volume (000s) | 31 | 482 | 25% |
|
| Price Change (52-week) |
(85.9%) | 59.9% | 5% |
|
| Growth | ERNA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 14.1% | na |
|
| Net Income (5yr) | (14.1%) | (10.1%) | 26% |
|
| EPS (5yr) | na | 15.9% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.6%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | ERNA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($12) | ($43) | 27% |
|
| EPS (TTM) | ($18.603) | ($1.500) | 3% |
|
| Operating Cash Flow (TTM) (Mil) | ($9) | ($31) | 21% |
|
| Net Cash Flow (TTM) (Mil) | $1 | $2 | 45% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 12% |
|
| Enterprise Value (Q1) (Mil) | $2 | $190 | 4% |
|
| Valuation | ERNA | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.58 | 2.84 | 40% |
|
| P/E | na | 20.2 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | ERNA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.9% | na |
|
| Net Margin | na | (74.2%) | na |
|
| ROA | (176.4%) | (47.7%) | 2% |
|
| ROE | (320.8%) | (55.0%) | 3% |
|
| Liabilities to Assets | 49.3% | 29.8% | 41% |
|
| F-Score | 2 | 3 | na |
|
Ernexa Therapeutics Inc. did not pass any screens on 9/4/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors
